Seaport begins phase 2a trial of GlyphAgo for generalized anxiety disorder with sleep disturbance, testing liver-sparing agomelatine dosing and tracking sleep, anxiety outcomes.
|Videos|October 29, 2020
The Pervasive Fear of Going to Work
Author(s)David “Daven” E. Morrison, MD
Keeping up your energy at work is difficult with the stressors of COVID-19, social unrest, and the upcoming election. As a mental health professional, how can you help alleviate this fear?
Advertisement
Dr Daven Morrison talks about the myriad of issues surrounding the current complex workplace.
Dr Morrison is Assistant Clinical Professor of Psychiatry at Chicago Medical School.
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Psychiatric Times
1
Olanzapine LAI (Weltruza) Receives FDA Approval for Schizophrenia
2
Moving Away From Treatment-Resistant Depression and Toward Difficult-to-Treat Depression
3
Two New MDD Approvals: 5-HT1A Agonism and Adjunctive Atypical Antipsychotics
4
Measurement-Informed Psychiatric Care: If Not Now, Then When?
5